TRDA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
905.0K
+0.8%
898.0K
+2.6%
875.0K
-32.6%
1.3M
-19.5%
1.6M
Cost of Revenue
0
0
0
0
0
Gross Profit
905.0K
+0.8%
898.0K
+2.6%
875.0K
-32.6%
1.3M
-19.5%
1.6M
Operating Expenses
42.6M
-7.1%
45.9M
+6.2%
43.2M
-0.8%
43.5M
-10.6%
48.7M
R&D
32.4M
-8.5%
35.4M
+7.0%
33.1M
-2.7%
34.0M
-11.5%
38.4M
SG&A
10.2M
-2.5%
10.5M
+3.6%
10.1M
+6.0%
9.6M
-7.3%
10.3M
Operating Income
-41689000
+7.3%
-44963000
-6.3%
-42303000
-0.2%
-42208000
+10.3%
-47051000
EBITDA
-41019000
+7.0%
-44122000
-6.3%
-41498000
-0.4%
-41322000
+9.8%
-45821000
Net Income
-39742000
+7.1%
-42763000
-7.7%
-39717000
-1.4%
-39164000
+11.3%
-44134000
EPS (Basic)
$-0.94
+6.9%
$-1.01
-6.3%
$-0.95
-1.1%
$-0.94
+11.3%
$-1.06
EPS (Diluted)
$-0.94
+6.9%
$-1.01
-6.3%
$-0.95
-1.1%
$-0.94
+11.3%
$-1.06
Shares (Diluted)
42.4M
+0.4%
42.2M
+0.9%
41.8M
+0.5%
41.6M
+0.4%
41.5M
Entrada Therapeutics (TRDA) — Financials